[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsonism-in-diseases-classified-elsewhere\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsonism-in-diseases-classified-elsewhere":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100629173",false,"NCT07471230","Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","Phase II Randomized Controlled Trial Evaluating Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","STEM-PARK","Inclusion Criteria:\n\nAge 40-80 years Clinical diagnosis of Parkinsonism Hoehn and Yahr stage II-III Stable pharmacological treatment for ≥3 months\n\nExclusion Criteria:\n\nAtypical parkinsonian syndromes unrelated to neurodegeneration History of malignancy within 5 years Severe cardiovascular disease Prior cellular therapy Active infection or immunosuppression","ALL","48 Years","70 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism.\n\nThe study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.",[27,28],"Parkinsonism or Parkinson's Disease Nos","Parkinsonism in Diseases Classified Elsewhere",[30,31,32,33],"mesenchymal","exosomes","parkinsonism","stem cells","NOT_YET_RECRUITING","2026-03-10",{"date":37,"type":38},"2026-03-13","ACTUAL",{"date":40,"type":21},"2026-11-23",{"date":42,"type":21},"2029-11-23",{"name":44,"class":45},"Biocells Medical","INDUSTRY",1,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100540511","NCT06317792","The Efficacy of Online Exergaming-Integrated Physiotherapy for Parkinson's Disease","Assessing the Efficacy of Online Exergaming-Integrated Physiotherapy for Parkinson's Disease: A Validation Study","Inclusion Criteria:\n\n1． Clinical diagnosis of Parkinson's disease\n\nExclusion Criteria:\n\n1. Moderate and severe dementia (Clinical Dementia Rating more than or equal to 2)\n2. Advanced PD stage (Hoehn and Yahr staging equal or more than four)",true,"20 Years","90 Years",{"count":57,"type":21},50,[59],"NA","To validate the efficiency of online exergaming-based physiotherapy. We will enroll patients with Parkinson's disease in postural instability and gait disturbance motor phenotype in the study and divide them into two groups in a randomized controlled study.",[28],[63,64],"online exergaming-based physiotherapy","Parkinson's disease","2024-03-12",{"date":67,"type":38},"2024-03-19",{"date":69,"type":21},"2024-04-01",{"date":71,"type":21},"2026-06-30",{"name":73,"class":74},"Chang Gung Memorial Hospital","OTHER",""]